Profund Advisors LLC Increases Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

Profund Advisors LLC raised its position in United Therapeutics Co. (NASDAQ:UTHR) by 73.1% during the second quarter, Holdings Channel.com reports. The fund owned 12,638 shares of the biotechnology company’s stock after purchasing an additional 5,338 shares during the quarter. Profund Advisors LLC’s holdings in United Therapeutics were worth $4,026,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of UTHR. ClariVest Asset Management LLC increased its holdings in United Therapeutics by 120.0% during the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 42 shares during the period. V Square Quantitative Management LLC bought a new position in shares of United Therapeutics during the second quarter valued at approximately $30,000. Rise Advisors LLC purchased a new stake in United Therapeutics in the first quarter worth $32,000. Innealta Capital LLC bought a new stake in United Therapeutics in the second quarter valued at $33,000. Finally, Benjamin F. Edwards & Company Inc. increased its position in United Therapeutics by 63.6% during the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company’s stock valued at $69,000 after purchasing an additional 117 shares during the period. 94.08% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. StockNews.com lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, August 2nd. TD Cowen increased their target price on United Therapeutics from $270.00 to $350.00 and gave the stock a “buy” rating in a research report on Thursday, July 11th. LADENBURG THALM/SH SH lowered United Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 1st. HC Wainwright reiterated a “buy” rating and issued a $400.00 price objective on shares of United Therapeutics in a report on Thursday, August 1st. Finally, Morgan Stanley lowered United Therapeutics from an “overweight” rating to an “equal weight” rating and raised their price objective for the company from $310.00 to $321.00 in a research report on Thursday, July 11th. One analyst has rated the stock with a sell rating, three have issued a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $350.36.

Insider Activity at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 25,000 shares of the company’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $323.38, for a total transaction of $8,084,500.00. Following the transaction, the chief operating officer now owns 2,577 shares in the company, valued at approximately $833,350.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other United Therapeutics news, Director Nilda Mesa sold 266 shares of the business’s stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $318.58, for a total transaction of $84,742.28. Following the completion of the sale, the director now directly owns 5,107 shares in the company, valued at approximately $1,626,988.06. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, COO Michael Benkowitz sold 25,000 shares of the firm’s stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $323.38, for a total value of $8,084,500.00. Following the completion of the transaction, the chief operating officer now owns 2,577 shares in the company, valued at $833,350.26. The disclosure for this sale can be found here. Insiders have sold 110,922 shares of company stock valued at $36,541,398 over the last ninety days. Insiders own 12.50% of the company’s stock.

United Therapeutics Stock Up 0.5 %

Shares of United Therapeutics stock opened at $353.00 on Friday. The company has a 50-day simple moving average of $339.19 and a two-hundred day simple moving average of $291.68. United Therapeutics Co. has a 52-week low of $208.62 and a 52-week high of $366.08. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.18 and a current ratio of 4.35. The stock has a market capitalization of $15.66 billion, a PE ratio of 16.69, a price-to-earnings-growth ratio of 1.25 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.33 by ($0.48). The business had revenue of $714.90 million during the quarter, compared to the consensus estimate of $691.87 million. United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The business’s revenue was up 19.8% compared to the same quarter last year. During the same period last year, the company posted $5.24 earnings per share. On average, analysts anticipate that United Therapeutics Co. will post 24.86 EPS for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.